Fulgent Genetics stock
FLGTNASDAQFulgent Genetics, Inc., HealthcareISIN US3596641098
36Score 36 out of 100, Weak
Price and trend
85 / 100
Price history
−15% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 30% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 19% below its 52-week high. Largest decline in 10 years: 92% (February 2021 to March 2026).
Chart figures for advanced users
- SMA 50$21.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$19.14
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.79
- The lowest closing price of the last twelve months.
- Resistance$30.85
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Fulgent Genetics, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $694.28M, is number 35 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $322.67M (up 13.8% year on year) and a loss of $60.51M.
- MEQIRI Score 36 out of 100 (Weak): rank 616 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $652.29M, financial debt $482K.Stability 57
Weaknesses
- Margin fallingOperating margin −28.2%, average of the prior years 28.8% (to 2024).Profitability 19
- DilutionShare count up 36% since 2020.Capital allocation 18
- Loss-makingLoss of $90.93M over the last 12 months.Fundamentals 23
Its standout strengths are technical analysis and momentum, while capital allocation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.7% on the twelve months before. Revenue has grown strongly since 2014, at around 65% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 41%, operating −28%, net −19%. Last 12 months: net −28%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 5 Nov 2026EPS reported −$0.09 (expected −$0.65)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.270.0%
- Revenue
- $331.7M0.0%
- Earnings per share
- −$1.380.0%
- Revenue
- $382.7M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −15.7%2026 revenue guidance lowered to $330 million to $340 million (from $350 million), gross margin now in the mid 30s, non-GAAP loss of $2.22 to $2.35 per share expected.
“We now expect total revenue to be in the range of $330 million to $340 million for 2026, down from our prior guidance of $350 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $154,902 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Fulgent Genetics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- NeoGenomicsNEO $2.19B40
- VeracyteVCYT $2.03B53
- PersonalisPSNL $1.73B41
- GeneDx HoldingsWGS $1.64B37
- OPKO HealthOPK $1.27B37
- Castle BiosciencesCSTL $1.05B43
- Myriad GeneticsMYGN $548.67M40
- VoxelVOX.WA $400.7M82
ETFs that hold Fulgent Genetics
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.43% | 0.68% | €5.31M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.28% | 0.50% | €127.06M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
Show 2 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.01% | 0.39% | €188.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.